Ubs Asset Management Americas Inc Nu Cana PLC Transaction History

Ubs Asset Management Americas Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$4.02 - $9.05 $732,845 - $1.65 Million	-182,300 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$5.55 - $8.48 $3,885 - $5,936	-700 Reduced 0.38%	182,300 $0
Q2 2019 Aug 15, 2019	SELL	$9.74 - $17.45 $43,830 - $78,525	-4,500 Reduced 2.4%	183,000 $0
Q1 2019 May 14, 2019	BUY	$10.92 - $18.03 $1,092 - $1,803	100 Added 0.05%	187,500 $0
Q4 2018 Feb 13, 2019	SELL	$13.0 - $22.57 $170,300 - $295,667	-13,100 Reduced 6.53%	187,400 $0
Q3 2018 Nov 14, 2018	SELL	$20.12 - $26.86 $891,316 - $1.19 Million	-44,300 Reduced 18.1%	200,500 $0
Q2 2018 Aug 14, 2018	SELL	$19.0 - $29.84 $495,900 - $778,824	-26,100 Reduced 9.63%	244,800 $0
Q1 2018 May 14, 2018	SELL	$10.04 - $28.25 $1.94 Million - $5.47 Million	-193,700 Reduced 41.69%	270,900 $0
Q4 2017 Feb 09, 2018	BUY	$10.0 - $18.72 $198,000 - $370,656	19,800 Added 4.45%	464,600 $0
Q3 2017 Nov 13, 2017	BUY	$16.15 - $18.37 $7.18 Million - $8.17 Million	444,800	444,800 $0

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $59M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.